AnGes, Inc.
OTC: AMGXF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ei Yamada
- Employees
- 55
- Headquarters
- Ibaraki, Japan
- IPO year
- 2017
- Market cap
- $142.5M
- Website
- https://www.anges.co.jp
Loading AMGXF…
Loading profile data…Frequently asked questions about AMGXF
What does AnGes, Inc. (AMGXF) do?
AnGes, Inc., a biopharmaceutical firm established in 1999 and headquartered in Ibaraki, Japan, specializes in the research and advancement of gene-based medical solutions. The company's flagship product is Hepatocyte Growth Factor (HGF) Plasmid, a pioneering gene therapy developed to address critical limb ischemia, a severe condition characteriz...
Where does AMGXF trade?
AnGes, Inc. (AMGXF) trades on the Other OTC.
What sector is AMGXF in?
AnGes, Inc. (AMGXF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AnGes, Inc.?
Ei Yamada is the chief executive officer of AnGes, Inc. (AMGXF).
Where is AnGes, Inc. headquartered?
AnGes, Inc. is headquartered in Japan.
Does AMGXF pay a dividend?
AnGes, Inc. (AMGXF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AMGXF go public?
AnGes, Inc. (AMGXF) completed its initial public offering in 2017.